European Journal Of Haematology · 2001 · 64 citations · 22 references
L1 had comparable efficacy as deferoxamine with minimal side effects and better compliance. Provided long term side effects are not encountered, L1 seems to be a valuable alternative iron chelator for patients unable or unwilling to use deferoxamine effectively.
22
Iron-Chelating Therapy and the Treatment of Thalassemia
Nancy F. Olivieri, Gary M. Brittenham · Blood · 1997 · 1.1K citations · Full text
Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients
A. V. Hoffbrand, F. N. Al‐Refaie, Bernard A. Davis et al. · Blood · 1998 · 205 citations · Full text